Do you routinely obtain CPS assay to assess candidacy for chemoimmunotherapy in newly diagnosed metastatic esophageal/GEJ/gastric adenocarcinoma?
Is it necessary to test CPS given the FDA approvals are not contingent on CPS %?
If you do test, do you check 28-8 (nivolumab), 22C3 (pembrolizumab), or both? Are you testing everyone at diagnosis?
If you don't test, what is your preferred treatment approach?
Community PollStarted
Which CPS assay will you use for assessing candidacy for chemoimmunotherapy in metastatic G/E/GEJ adenocarcinoma?
71 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Medical Oncology · City of Hope Comprehensive Cancer Care
Answered on
I am still apt to assess tumor PD-L1 CPS to help inform long-term benefit from first-line chemoimmunotherapy in a patient with metastatic disease. Intrapatient, interlesional heterogeneity for PD-L1 CPS has also been recognized in the literature corresponding to discordance in levels of PD-L1 CPS po...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · NYU School of Medicine
Answered on
Even though FDA approval is not contingent on CPS score, it would still be a good idea to test for it. I test all patients at diagnosis of metastatic disease, and use assay 28-8 for nivolumab, as I intend to use nivolumab and chemotherapy as my preferred treatment approach.
Join for free or sign in to see the full answer